Treatment Strategies in Early and Advanced Parkinson Disease

Ossig, Christiana; Reichmann, Heinz

doi:10.1016/j.ncl.2014.09.009

Cited by 29 publications

(19 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonergot DAs are commonly used as monotherapy in younger and mildly symptomatic PD patients. 1,28,29 Impulsivity, cognitive impairment, and somnolence are known adverse events associated with nonergot DAs. 1,[30][31][32] Our data add to the growing body of pharmacovigilance literature that suggests cardiac diagnoses may be more common among DA users.…”

Section: Discussionmentioning

confidence: 99%

“…1,28,29 Impulsivity, cognitive impairment, and somnolence are known adverse events associated with nonergot DAs. 1,[30][31][32] Our data add to the growing body of pharmacovigilance literature that suggests cardiac diagnoses may be more common among DA users. Phase II/III clinical trial data demonstrated a higher frequency of HF among pramipexole users versus placebo, but this difference was Adjusted for census category, hospital teaching status, congestive HF, cardiac arrhythmia, valvular disease, pulmonary circulation disorders, hypertension complicated, hypothyroidism, renal failure, peptic ulcer disease-excluding bleeding, coagulopathy, weight loss, fluid and electrolyte disorders, and blood loss anemia.…”

Section: Discussionmentioning

confidence: 99%

“…After levodopa (LD), dopamine agonists (DAs) are drugs most frequently used in the treatment of Parkinson's disease (PD). They are classified as ergot derivatives (bromocriptine, cabergoline, lisuride, and pergolide) or nonergot derivatives (apomorphine, piribedil, pramipexole, ropinirole, and rotigotine) and may be used alone or as adjunct therapy …”

mentioning

confidence: 99%

See 2 more Smart Citations

Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease

Crispo

Willis

Thibault

et al. 2015

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Knowledge of possible cardiovascular risks from Parkinson's disease (PD) medications is critical to informing safe and effective treatment decisions. The objective of our study was to determine whether PD patients treated with nonergot dopamine agonists (DAs) are at increased risk of adverse cardiovascular or cerebrovascular outcomes, relative to PD patients receiving other treatments. Methods Matched case‐control studies were conducted within a cohort of 14,122 inpatients receiving treatment for PD who were identified in the Cerner Health Facts database. Primary outcomes were associations between nonergot DA use and diagnosis of adverse cardiovascular events (acute myocardial infarction, heart failure [HF], hypotension, and valvulopathy). Secondary outcomes included associations between nonergot DA use and diagnosis of adverse cerebrovascular events (cerebrovascular accident and ischemic stroke) and odds of significant exposure‐outcome relationships by patient factors. Results HF was the only adverse event that demonstrated a significant association with nonergot DA use. Individuals treated with pramipexole were more likely to be diagnosed with HF, relative to no use (adjusted odds ratio [AOR]: 1.28; 95% confidence interval [CI]: 1.07–1.53). The association between pramipexole and HF was greater among individuals treated with pramipexole monotherapy (relative to levodopa monotherapy) (AOR, 1.50; 95% CI: 1.09–2.06). Compared to nonusers, men and older individuals treated with pramipexole were more likely to be diagnosed with HF. Conclusions Results from our study suggest an association between pramipexole use and HF. Findings warrant replication; however, individuals with PD and independent risk factors for, or a history of, HF may benefit from limited use of this drug.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease

Crispo

Willis

Thibault

et al. 2015

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…These alterations lead to a progressive loss of dopaminergic neurons and the clinical signs of illness [63][64][65][66][67][68]. However, these pathologic changes are not limited to the substantia nigra pars compacta.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Neurochemical correlation between major depressive disorder and neurodegenerative diseases

et al. 2016

View full text Add to dashboard Cite

“…Age is the most common risk factor for PD and given that the population ages, the incidence of this disease is predicted to double by 2040 (Gustavsson et al, 2011;Kowal et al, 2013;von Campenhausen et al, 2005). Several symptomatic treatments for PD exist, but their effect is limited in time as the disease relentlessly progresses (Athauda and Foltynie, 2014;Ossig and Reichmann, 2015). Hence, a better understanding of the underlying pathology is needed to arrive at more powerful disease modifying strategies.…”

Section: Introductionmentioning

confidence: 99%